{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:17:55Z","timestamp":1772792275820,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:00:00Z","timestamp":1699488000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>All patients treated with anticancer agents should receive the most effective anti\u2010emetic regimen. Anti\u2010emetic guidelines provide recommendations but do not take into account possible drug\u2013drug interactions between anti\u2010emetics and anticancer drugs. This study determines the clinical relevance of the potential drug\u2013drug interaction of the neurokinin\u20101 receptor antagonist, aprepitant, on the pharmacokinetics of etoposide. Aprepitant is a moderate CYP3A4 inhibitor and may increase the systemic exposure of etoposide which is partly metabolized by cytochrome P450 enzyme 3A4 (CYP3A4). In this prospective observational study, the pharmacokinetics of etoposide with and without concomitant use of aprepitant was determined in 12 patients receiving first\u2010line chemotherapy for testicular cancer. The geometric mean (95% confidence interval (CI)) area under the plasma concentration\u2010time curve 0\u201324\u2009hour (AUC<jats:sub>0\u201324h<\/jats:sub>) of etoposide with aprepitant was 86.2 (79.7\u201393.2) mg\/L*hour vs. 83.7 (75.8\u201392.4) mg\/L*hour without aprepitant. Geometric mean ratios (90% CIs) of AUC<jats:sub>0\u201324h<\/jats:sub> and maximum plasma concentration (<jats:italic>C<\/jats:italic><jats:sub>max<\/jats:sub>) for etoposide with and without aprepitant were 1.03 (0.96\u20131.10) and 0.96 (0.89\u20131.03), respectively. This study confirms the absence of a clinically relevant interaction between etoposide and aprepitant. Both drugs can be safely combined without affecting etoposide exposure.<\/jats:p>","DOI":"10.1002\/cpt.3081","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T04:44:05Z","timestamp":1698036245000},"page":"135-138","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effect of Aprepitant on Etoposide Pharmacokinetics in Patients with Testicular Cancer: A Pharmacokinetic Study to Determine the Absence of a Clinically Relevant\u00a0Interaction"],"prefix":"10.1002","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0548-9899","authenticated-orcid":false,"given":"Jeffrey","family":"Strik","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Radboud University Medical Center Research Institute for Medical Innovation Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3989-8386","authenticated-orcid":false,"given":"Loek A. W.","family":"de Jong","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud University Medical Center Research Institute for Medical Innovation Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joost","family":"Sijm","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Radboud University Medical Center Research Institute for Medical Innovation Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0945-8299","authenticated-orcid":false,"given":"Ingrid M. E.","family":"Desar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Radboud University Medical Center Research Institute for Medical Innovation Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1553-178X","authenticated-orcid":false,"given":"Nielka P.","family":"van Erp","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Radboud University Medical Center Research Institute for Medical Innovation Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,11,9]]},"reference":[{"key":"e_1_2_8_1_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2019.0058"},{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01296"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw270"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-1-46"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2020.100278"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13322"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.128"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.01.095"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11433"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.5558"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00123-1"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007300807"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003262950"},{"key":"e_1_2_8_14_1","first-page":"352","article-title":"O\u2010demethylation of epipodophyllotoxins is catalyzed by human cytochrome P450 3A4","volume":"45","author":"Relling M.V.","year":"1994","journal-title":"Mol. Pharmacol."},{"key":"e_1_2_8_15_1","unstructured":"Food and Drug Administration.Drug label Emend (aprepitant). <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021549s030207865s003lbl.pdf> (2019) Accessed August 14 2023."},{"key":"e_1_2_8_16_1","unstructured":"Food and Drug Administration.Drug label Akynzeo (netupitant\/palonosetron)<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/205718s000lbl.pdf> (2014) Accessed August 14 2023."},{"key":"e_1_2_8_17_1","first-page":"2742","article-title":"Inter\u2010 and intrapatient variability in etoposide kinetics with oral and intravenous drug administration","volume":"5","author":"Hande K.","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"e_1_2_8_18_1","unstructured":"US Department of Health and Human Services.Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Guidance for Industry. Statistical Approaches to Establishing Bioequivalence. <https:\/\/www.fda.gov\/media\/70958\/download> (2001) Accessed August 1 2022."},{"key":"e_1_2_8_19_1","unstructured":"Flockhart D.A.T.D. McDonald C.&Desta Z.The Flockhart Cytochrome P450 Drug\u2010Drug Interaction Table. Division of Clinical Pharmacology Indiana University School of Medicine (Updated 2021). <https:\/\/drug\u2010interactions.medicine.iu.edu>. Accessed 2022."},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.01513.x"},{"key":"e_1_2_8_21_1","unstructured":"Food and Drug Administration.Drug label Vepesid (etoposide)<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2002\/019557s028lbl.pdf> (2002) Accessed August 14 2023."},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e32832e0e7f"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00685638"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-013-1855-y"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010387792"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,31]],"date-time":"2023-12-31T05:43:24Z","timestamp":1704001404000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,9]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1002\/cpt.3081"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3081","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,9]]},"assertion":[{"value":"2023-06-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}